Back to results
US 12,528,862 B2Granted
Anti-interferon gamma antibodies and uses thereof
AssigneeElixiron Immunotherapeutics (Hong Kong) Limited
InventorsCheng-Lun Ku, Han-Po Shih, Chia-Hao Lin, Jing-Ya Ding, Jing-Yi Huang, Yi-Ting Kuo
Life of this patent
Estimating the term…
Abstract
Provided is an anti-INF-γ antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-γ mediated syndrome.
Claims4
An engineered polynucleotide encoding an anti-interferon-γ (IFN-γ) antibody in a genetically engineered mammalian host cell, the polynucleotide comprising:
- (i) a first nucleotide sequence encoding a heavy chain variable region (VH) of the antibody, and
- (ii) a second nucleotide sequence encoding a light chain variable region (VL) of the antibody;
- wherein the VH and VL comprise complementarity determining regions (CDRs) selected from:
- (a) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 120, 121, and 122, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 132, 133, and 134, respectively;
- (b) VH CDR1, VH CDR2, and VH CDR3 are SEQ ID NO:
- 144, 145, and 146, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 156, 157, and 134, respectively;
- (c) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 123, 124, and 125, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 135, 136, and 137, respectively;
- (d) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 147, 148, and 149, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 158, 159, and 137, respectively;
- (e) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 120, 121, and 122, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 135, 136, and 137, respectively;
- (f) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 144, 145, and 146, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 158, 159, and 137, respectively;
- (g) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 123, 124, and 125, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 132, 133, and 134, respectively;
- or
- (h) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 147, 148, and 149, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 156, 157, and 134, respectively;
- and
- wherein the first nucleotide sequence has at least 90% identity to SEQ ID NO:
- 173, 175, 176, 177, 179, or 181;
- wherein the second nucleotide sequence has at least 90% identity to SEQ ID NO:
- 174, 178, 180, or 182;
- and
- wherein the antibody encoded by the engineered polynucleotide specifically binds to IFN-γ, and
- wherein the genetically engineered mammalian host cell is selected from the group consisting of a Chinese Hamster Ovary (CHO) cell, NSO cell, BHK cell, SP2/0 cell, HEK 293 cell, HEK 293 EBNA cell, and COS cell.
41 more elements
A genetically engineered mammalian host cell expressing an anti-IFN-γ antibody, wherein the genetically engineered mammalian host cell comprises an engineered polynucleotide encoding the antibody, the antibody comprising:
- (i) a heavy chain variable region (VH);
- and
- (ii) a light chain variable region (VL);
- wherein the VH and VL comprise complementarity determining regions (CDRs) selected from:
- (a) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 120, 121, and 122, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 132, 133, and 134, respectively;
- (b) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 144, 145, and 146, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 156, 157, and 134, respectively;
- (c) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 123, 124, and 125, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 135, 136, and 137, respectively;
- (d) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 147, 148, and 149, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 158, 159, and 137, respectively;
- (e) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 120, 121, and 122, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 135, 136, and 137, respectively;
- (f) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 144, 145, and 146, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 158, 159, and 137, respectively;
- (g) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 123, 124, and 125, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 132, 133, and 134, respectively;
- or
- (h) VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO:
- 147, 148, and 149, respectively;
- and VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO:
- 156, 157, and 134, respectively;
- wherein the antibody encoded by the engineered polynucleotide specifically binds to IFN-γ, and
- wherein the genetically engineered mammalian host cell is selected from the group consisting of a Chinese Hamster Ovary (CHO) cell, NSO cell, BHK cell, SP2/0 cell, HEK 293 cell, HEK 293 EBNA cell, and COS cell.
36 more elements
Dependencies are inferred from the claim text.